The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development

(2010) Elena Soto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prediction of Neutropenia-Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed

(2010) E Soto et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Targeted therapy in lymphoma

(2010) Patrick B Johnston et al.   Journal of Hematology & Oncology

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

(2009) Mark Prichard et al.   EXPERT OPINION ON PHARMACOTHERAPY

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY